Diabetic Foot Ulcer Treatment Market Size, Share & Covid-19 Impact Analysis, By Ulcer Type (Neuropathic Ulcer, Ischemic Ulcer, Neuro-ischemic Ulcer), By Product (Wound-care Dressings, Wound-care Devices, Active Therapies, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Homecare Settings), and Regional Forecast, 2020-2027

The global diabetic foot ulcer treatment market size was valued at USD 7.03 billion in 2019 and is projected to reach USD 11.05 billion by 2027, exhibiting a CAGR of 5.9% during the forecast period.

A diabetic foot ulcer is a well-known potential complication for patients with poorly controlled diabetes. The major underlying causes are peripheral neuropathy and ischemia from peripheral vascular diseases. 

The diabetic foot ulcer treatment market is majorly driven by factors such as the rapidly increasing prevalence of diabetic foot ulcers and the growing adoption of novel wound care devices for its treatment. According to an article published by the National Center for Biotechnology Information (NCBI) in 2017, it was estimated that the prevalence of diabetic foot ulcers was 6.3% across the globe. The increasing awareness about the availability of treatment options for DFU, rise in healthcare expenditures, and an increase in advanced treatment procedures are anticipated to boost the market during the forecast period. Combined with this, the growing geriatric population and rise in demand for multiple treatment options by patients diagnosed around the globe are likely to increase the DFU treatment market size during the forecast period.

Diabetic Foot Ulcer Treatment amid COVID-19 Pandemic: Decline in Non-Emergency Procedures

Certain medical device segment is likely to showcase a significant impact due to the coronavirus pandemic owing to the slowdown in non-emergency procedures and healthcare services. In March 2020, the U.S. Surgeon General, the Centers for Medicare and Medicaid Services (CMS), and the American College of Surgeons all recommended delaying or cancelling non-essential medical and surgical services to reduce the exposure risk of the virus.

With respect to this, many countries have reallocated healthcare resources such as hospital beds, nurses, essential personnel, and medical devices for the management of COVID-19 patients. This has resulted in the temporary exclusion of wound care services from the essential procedures list. It is important to acknowledge the non-limb threatening complication of this type of foot ulcer and make arrangements to be treated at home or through telemedicine. This has led to a significant impact on the number of patient visits to wound care centers, and outpatient departments, especially in the U.S., and European countries. According to a statistics published by Today’s Wound Clinic., open fully-staffed wound care centers are witnessing a drop in patient volume by 40% during the ongoing COVID19 pandemic.

The COVID-19 outbreak has therefore negatively impacted the market. The global diabetic foot ulcer treatment market is projected to grow by only 5.6% in 2020 due to the COVID-19 crisis as compared to 6.3% without the COVID-19 pandemic.

LATEST TRENDS

Request a Free sample to learn more about this report.

Launch of New Active Therapies by Key Players to Fuel Demand

Chronic foot ulceration is a major source of amputation in diabetic patients. These wounds benefit from latest introduction of active therapies, growth factors, and allograft. They have an established and clinically proven efficiency in treatment of hard-to-heal chronic wounds. Currently, some of the major players operating in this segment are involved in research and development of these therapies in the market. For instance, in February 2020, Integra LifeSciences Corporation announced the launch of AmnioExcel Plus Placental Allograft Membrane, its latest wound care product offering treatment of complex wounds.

DRIVING FACTORS

Increasing Prevalence of Diabetic Foot Ulcer to Accelerate Growth

A diabetic foot ulcer is one of the most significant and devastating complications of diabetes. Along with the rising prevalence of diabetes, an increase in its complications is witnessed. Various factors such as advancing age, sedentary lifestyle, and longer duration of diabetes mellitus have been responsible for increasing the prevalence of these ulcers. According to an article published in 2019 by the National Center for Biotechnology Information (NCBI), the prevalence of this type of ulcer in North America is 13%, the annual incidence of necrosis in diabetic patients is about 2-5%; and the lifetime risks ranges between 15 to 20%.  These trends are presenting a large patient pool seeking treatment. This, along with the increasing awareness about the availability of treatment and rise in healthcare expenditure among the patient population, especially in emerging countries is anticipated to further augment the market during the forecast period.

Technological Advancements in Treatment Options, especially in Developed Economies to Drive Market

Diabetic foot ulcer belongs to the most frequent complication of diabetes and is one of the major causes of morbidity worldwide. Continuous technological advancements in the treatment options such as bioengineered skin substitutes, extracellular matrix proteins, and miscellaneous therapeutic agents are projected to augment growth. For instance, in July 2019, AVITA Medical, a global regenerative medicine company, announced favorable results from an open-label feasibility study of the RECELL Autologous Cell Harvesting Device (RECELL System) for the treatment of DFUs.

Clinical trials with Dermagraft, Apligraf, and Lamin gel have yielded favorable results for the treatment. Therefore, the growing number of such technological advances is anticipated to aid in expansion of the market growth during the forecast period.

RESTRAINING FACTORS

High Cost of the Advanced Wound Care Devices and Therapies to Hamper the Market Expansion

In the current scenario, although there is rising prevalence of this condition globally, certain factors are restraining growth. One among them is the high cost of the advanced wound care devices and limited reimbursement available for these products in the developing regions. For instance, according to the economic analysis, the overall cost of wound care dressing is around USD 3 whereas the cost of NPWT pumps is around USD 90 in U.S.

SEGMENTATION

By Ulcer Type Outlook

Neuroischemic Ulcer Segment Expected to Dominate Market due to Growing Number of Cases

Based on ulcer type, the market is segmented into a neuropathic ulcer, ischemic ulcer, and neuroischemic ulcer. Among them, the neuroischemic ulcer segment is expected to dominate the market during the forecast period owing to the high prevalence and subsequent higher treatment costs. For instance, according to a study by the National Center for Biotechnology Information (NCBI), the treatment expenses for neuropathic foot ulcer and neuroischemic diabetic foot ulcer are USD 56 and USD 1,960, respectively.

On the other hand, the ischemic segment is anticipated witness a comparatively sluggish growth due to fewer occurrences of this case as compared to the other two types. For instance, according to a study by the World Journal of Diabetes, pure ischemic ulcer accounts for only 10% of the diabetic foot ulcer and 90% are caused by neuropathy, alone or with ischemia.

By Product Type Outlook

To know how our report can help streamline your business, Speak to Analyst

Wound Care Dressings Segment to Hold Leading Market Share due to High Efficacy of Dressings and Low Cost

Among product type, the wound care dressing segment is expected to dominate the market. Increased focus of market players on research and development, rise in launch of technologically advanced products, growing awareness about these products in emerging regions, and surge in per capita healthcare expenditure are the prominent factors driving this segment. The wound care devices segment is projected to expand at a considerably high growth rate, adoption of negative pressure wound therapy and the introduction of new therapies including extracorporeal shock wave therapy for wound care. Distinct advantages of wound care devices in exudate management, reduced healing time of the wound, and comparatively lower care cost for wound management are factors anticipated to increase the adoption of new wound care devices during the forecast period.

On the other hand, the active therapies segment includes skin grafts & substitutes, growth factors, hemostatic agents, and sealants. Skin grafts and substitutes that involves processes such as taking the healthy skin from another area of the body and placing it over the ulcer is also used as a treatment option. Thus, novel applications of these treatment therapies are anticipated to boost their adoption rates, further fueling the growth of this segment.

By End User Outlook

Hospitals Segment to Continue Its Dominance till 2026 in the Global Market

On the basis of end-user, the market is segmented into hospitals, clinics, ambulatory surgical centers, and home care settings. The hospital segment is anticipated to emerge dominant during the forecast period. This is due to the higher adoption rate of treatment options for diabetic foot ulcers in hospitals, presence of required facility skilled staff, and increasing patient preference to hospitals due to favorable policies.

The homecare setting segment is expected to exhibit the fastest growth rate owing to the rise in the geriatric patient population and shift in preference from a hospital set up to self-care at home care settings. The clinics segment is likely to expand at a considerable rate owing to increasing number of specialty clinics with advanced facilities, trained staff, and personalized wound care.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

Geographically, the market segments include North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among them, North America earned a dominant diabetic foot ulcer treatment market share and registered a revenue of USD 2.79 billion in the year 2019. This is attributable to the increasing prevalence of this type of ulcer, huge healthcare expenditure, high cost of products, and increasing launch of advanced technologies in this region.

Europe accounted for the second-largest share attributable to the increasing prevalence of diabetic foot ulcers among the adults and the geriatric population. Combined with this, an increase in the adoption of technologically advanced treatment options in countries like Germany, France, and the U.K. are expected to create growth opportunities for the market in the forthcoming years.

On the other hand, Asia Pacific is projected to register a higher CAGR during the forecast period due to the rapidly increasing geriatric population, and growing incidences of diabetic foot ulcers among the diabetic population. For instance, the United Nations Population Fund (UNFPA), currently stated that the geriatric population in Asia Pacific is rising at an unprecedented rate. It also states that by 2050, one in four people of the total population in this region will be above 60 years of age. Latin America and the Middle East & African regions, on the other side are anticipated to witness a moderate CAGR during the forecast period owing to the rising unmet needs for cost-effective treatment options for this type of ulcer and developing healthcare infrastructure. Moreover, the growing expansion of product offerings by many key players is likely to help attract high DFU treatment market revenue in the region during the forecast period.

KEY INDUSTRY PLAYERS

Smith & Nephew, ConvaTec Group Plc, and Coloplast Corp, Dominate the Market

Smith & Nephew, ConvaTec Group Plc, Coloplast Corp, and Mölnlycke Health Care AB. are the leading players in the market. This is accountable to the strong brand presence, combined with a wide range of product offerings. These players are likely to continue their dominance and generate significant revenue in the forthcoming years owing to the robust research activities and continuous investments in innovative product development. Moreover, a strong focus on strategic partnerships with other players is likely to support the expansion of their footprints in the market. For instance, in July 2018, Mölnlycke Health Care AB acquired a German wound care products company, SastoMed GmbH., to expand its product offerings of diabetic foot ulcer treatment.

Other players involved in market with a considerable share include 3M, Integra LifeSciences Corporation, and Cardinal Health.

LIST OF KEY COMPANIES PROFILED:

• Smith & Nephew (London, U.K.)


• ConvaTec Group Plc (England, U.K.)


• Coloplast Corp (Humlebaek, Denmark)


• Mölnlycke Health Care AB (Gothenburg, Sweden)


• 3M (Minnesota, United States)


• Integra LifeSciences Corporation (New Jersey, United States)


• Cardinal Health. (Ohio, United States)


• Tissue Regenix (West Yorkshire, U.S.)


• B. Braun Melsungen AG (Melsungen, Germany)


• Other Prominent Players

KEY INDUSTRY DEVELOPMENTS:

• December 2019: Orpyx Medical Technologies Inc. launched Orpyx SI Sensory Insoles with remote patient monitoring for the prevention of diabetic foot ulcer and neuropathy-related ulcers.


• July 2018: Mölnlycke acquired German wound care products company, SastoMed GmbH., with an aim to expand its product offerings to help patients and healthcare professionals to accelerate the wound healing process; and treating chronic wounds such as diabetic foot ulcer.


• January 2019 – UPM launched a new advanced wound care product in the European market. FibDex is the first wound dressing created from wood-based nanofibrillar cellulose to receive regulatory approval and to be awarded with a CE mark.


• December 2017: SANUWAVE Health, Inc. received FDA approval for marketing of the Dermapace System, the first shock wave device intended to treat diabetic foot ulcers.

REPORT COVERAGE

An Infographic Representation of Diabetic Foot Ulcer (DFU) Treatment Market

View Full Infographic

To get information on various segments, share your queries with us

The diabetic foot ulcer market report provides detailed information regarding various insights into the market. Some of them are growth drivers, restraints, competitive landscape, regional analysis, and challenges. It further offers an analytical depiction of the global market trends and estimations to illustrate the forthcoming investment pockets. The market is quantitatively analyzed from 2020 to 2027 to provide the financial competency of the market. The information gathered in this report has been taken from several primary and secondary sources.

Report Scope & Segmentation